

Yusuke Okuma

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/355591/yusuke-okuma-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

100
papers

1,084
citations

17
h-index

29
g-index

121
ext. papers

1,490
ext. citations

4
avg, IF

4.78
L-index

#	Paper	IF	Citations
100	Uncommon mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901).. <i>Future Oncology</i> , 2022 ,	3.6	1
99	Performance of Japanese patients in registrational studies.. <i>Japanese Journal of Clinical Oncology</i> , 2022 , 52, 53-64	2.8	
98	Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. <i>Cancers</i> , 2022 , 14, 2519	6.6	1
97	CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets.. <i>Frontiers in Oncology</i> , 2021 , 11, 808396	5.3	0
96	Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis.. <i>Frontiers in Oncology</i> , 2021 , 11, 779700	5.3	2
95	Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients. <i>Anticancer Research</i> , 2021 , 41, 5739-5747	2.3	0
94	Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.. <i>European Journal of Cancer</i> , 2021 , 162, 1-10	7.5	2
93	Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma. <i>Thoracic Cancer</i> , 2021 , 12, 1668-1672	3.2	2
92	Feasibility of next-generation sequencing (OncomineDX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2021 , 51, 1114-1122	2.8	7
91	Alectinib for Miliary Lung Metastasis in -Positive Lung Adenocarcinoma. <i>OncoTargets and Therapy</i> , 2021 , 14, 2911-2915	4.4	0
90	Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9061-9061	2.2	
89	Differential immune-related microenvironment determines PD-1/PD-L1 blockade efficacy in advanced non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9044-9044	2.2	2
88	A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug conjugate) in patients with PTK7-expressing, recurrent non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS3142-TPS3142	2.2	1
87	Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	0
86	Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment. <i>British Journal of Cancer</i> , 2021 , 124, 925-932	8.7	3
85	A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2021 , 27, 2571-2583	12.9	5
84	IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients. <i>Cancer Science</i> , 2021 , 112, 1534-1544	6.9	6

83	Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma. <i>Clinical Lung Cancer</i> , 2021 , 22, 282-291.e6	4.9	4
82	Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	0
81	Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated -mutated advanced non-small cell lung cancer: a prospective observational study. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3582-3593	4.4	1
80	Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. <i>Scientific Reports</i> , 2021 , 11, 18762	4.9	2
79	High Serum OX40 and OX40 Ligand (OX40L) Levels Correlate with Reduced Survival in Patients with Advanced Lung Adenocarcinoma. <i>Oncology</i> , 2020 , 98, 303-310	3.6	7
78	Two cases of granuloma mimicking local recurrence after pulmonary segmentectomy. <i>Journal of Cardiothoracic Surgery</i> , 2020 , 15, 7	1.6	3
77	The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 777-785	4.9	17
76	Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020 , 140, 28-36	7.5	6
75	Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy. <i>Lung Cancer</i> , 2020 , 148, 122-128	5.9	3
74	The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020 , 8, 1243-1250	12.5	53
73	Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma. <i>Cancer Medicine</i> , 2020 , 9, 7418-7427	4.8	3
72	High Serum Soluble CD27 Level Correlates with Poor Performance Status and Reduced Survival in Patients with Advanced Lung Cancer. <i>Oncology</i> , 2019 , 97, 365-372	3.6	6
71	Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2019 , 8, 450-460	4.4	8
70	Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202). <i>Japanese Journal of Clinical Oncology</i> , 2019 , 49, 749-754	2.8	2
69	Development of Hepatocellular Carcinoma During Nivolumab Treatment for Recurrent Non-Small Cell Lung Cancer: A Case Report. <i>Tohoku Journal of Experimental Medicine</i> , 2019 , 247, 247-250	2.4	2
68	A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 351-358	3.5	5
67	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. <i>International Journal of Clinical Oncology</i> , 2019 , 24, 731-770	4.2	63
66	Molecular and Morphological Profiling of Lung Cancer: A Foundation for "Next-Generation" Pathologists and Oncologists. <i>Cancers</i> , 2019 , 11,	6.6	20

65	Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer. <i>Oncology Letters</i> , 2019 , 17, 2946-2952	2.6	50
64	Genetic and immunohistochemical analyses of ciliated muconodular papillary tumors of the lung: A report of five cases. <i>SAGE Open Medical Case Reports</i> , 2019 , 7, 2050313X19830483	0.7	1
63	Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report. <i>Immunotherapy</i> , 2019 , 11, 467-472	3.8	17
62	Radiographic Assessment of Objective Responses Using the ITMIG-Modified Criteria in Thymic Carcinoma. <i>Oncology</i> , 2019 , 97, 264-269	3.6	
61	Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Thoracic Disease</i> , 2019 , 11, 2350-2360	2.6	19
60	Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 2555-2564	4.9	5
59	Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer. <i>Case Reports in Oncology</i> , 2019 , 12, 171-177	1	
58	Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing. <i>Lung Cancer</i> , 2019 , 128, 20-25	5.9	1
57	Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study). <i>Thoracic Cancer</i> , 2019 , 10, 395-400	3.2	7
56	Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status. <i>OncoTargets and Therapy</i> , 2019 , 12, 15-19	4.4	1
55	Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: An observational study. <i>Molecular and Clinical Oncology</i> , 2019 , 10, 137-143	1.6	24
54	Immune checkpoint inhibitors: the next step for thymic carcinomas. <i>Lancet Oncology, The</i> , 2018 , 19, 274-275		
53	Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. <i>Clinical and Translational Oncology</i> , 2018 , 20, 966-974	3.6	18
52	Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report. <i>BMC Cancer</i> , 2018 , 18, 302	4.8	13
51	Response to "Immune-mediated cholangitis: is it always nivolumab's fault?". <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 1329-1330	7.4	
50	Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study. <i>Oncologist</i> , 2018 , 23, 1210-1217	5.7	9
49	Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 61-65	7.4	45
48	Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018 , 19, 410-417.e1	4.9	70

47	Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018 , 38, 1077-1083	2.3	4
46	High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 495-505	7.4	10
45	Prognostic effects of osteoclast inhibitors in extensive stage small cell lung cancer patients with bone metastases. <i>Molecular and Clinical Oncology</i> , 2018 , 9, 561-565	1.6	1
44	Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1601-1611	4.9	6
43	Thymic Carcinoma With Endobronchial Metastasis: A Case Report. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2017 , 24, 159-162	1.8	5
42	High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. <i>Lung Cancer</i> , 2017 , 104, 1-6	5.9	110
41	Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib. <i>Japanese Journal of Clinical Oncology</i> , 2017 , 47, 357-362	2.8	5
40	Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature. <i>Case Reports in Oncology</i> , 2017 , 10, 333-338	1	6
39	Chemoradiotherapy for unresectable cases of thymic epithelial tumors: a retrospective study. <i>Journal of Thoracic Disease</i> , 2017 , 9, 3911-3918	2.6	3
38	Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604. <i>BMC Cancer</i> , 2017 , 17, 377	4.8	7
37	Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report. <i>Lung Cancer</i> , 2016 , 99, 148-50	5.9	41
36	Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors. <i>Medical Oncology</i> , 2016 , 33, 129	3.7	13
35	Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma. <i>BMC Cancer</i> , 2016 , 16, 156	4.8	8
34	A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 383-8	3.5	8
33	Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 559-64	3.5	5
32	Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations. <i>International Journal of Clinical Oncology</i> , 2016 , 21, 531-8	4.2	3
31	Cellulitis-like symptoms manifested by bone metastasis of lung cancer in a patient living with human immunodeficiency virus. <i>International Journal of STD and AIDS</i> , 2016 , 27, 912-6	1.4	1
30	A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report. <i>OncoTargets and Therapy</i> , 2016 , 9, 6059-6063	4.4	4

29	Osseous oligometastases from thymic carcinoma: a case report suggesting the effectiveness of palliative-intent radiotherapy treatment. <i>OncoTargets and Therapy</i> , 2016 , 9, 1029-32	4.4	4
28	Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1. <i>OncoTargets and Therapy</i> , 2016 , 9, 5287-95	4.4	2
27	Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review. <i>BMC Cancer</i> , 2016 , 16, 718	4.8	7
26	Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis. <i>Thoracic Cancer</i> , 2016 , 7, 39-43	3.2	11
25	Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015 , 141, 323-31	4.9	42
24	A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. <i>European Journal of Cancer</i> , 2015 , 51, 1904-10	7.5	14
23	Response to cytotoxic chemotherapy in patients previously treated with palliative-intent chemotherapy for advanced thymic carcinoma. <i>Clinical Lung Cancer</i> , 2015 , 16, 221-7	4.9	9
22	A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015 , 141, 1669-78	4.9	8
21	Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2015 , 8, 1321-5	4.4	12
20	Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014. <i>BMC Cancer</i> , 2015 , 15, 740	4.8	4
19	Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodeficiency virus. <i>OncoTargets and Therapy</i> , 2015 , 8, 111-5	4.4	8
18	Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center. <i>BMC Cancer</i> , 2014 , 14, 349	4.8	18
17	The potency of curative-intent treatment for advanced thymic carcinoma. <i>Lung Cancer</i> , 2014 , 84, 175-81	5.9	13
16	Crucial role of treatment with palliative intent for a patient with advanced thymic carcinoma. <i>Oncology Letters</i> , 2014 , 8, 513-516	2.6	4
15	Clinical outcome of thymic lymphoepithelioma-like carcinoma: Case report of a 14-year-old male. <i>Oncology Letters</i> , 2014 , 8, 2183-2186	2.6	12
14	A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer. <i>Oncologist</i> , 2014 , 19, 1194-9	5.7	14
13	A case of successful preoperative chemotherapy with cisplatin and irinotecan followed by curative-intent surgery for locally advanced thymic carcinoma. <i>General Thoracic and Cardiovascular Surgery</i> , 2013 , 61, 166-9	1.6	
12	Clinical outcomes with chemotherapy for advanced thymic carcinoma. <i>Lung Cancer</i> , 2013 , 80, 75-80	5.9	39

11	Concomitant chemoradiotherapy and antiretroviral therapy for HIV-infected patients with locoregionally advanced non-small cell lung cancer: benefit and tolerability of treatment in 2 cases. <i>Onkologie</i> , 2013 , 36, 586-90		3
10	Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study. <i>PLoS ONE</i> , 2013 , 8, e59700	3-7	12
9	A Case Report of an EML4-ALK-positive Elderly Non-small Cell Lung Cancer Patient with a Poor PS Successfully Treated with Crizotinib. <i>Japanese Journal of Lung Cancer</i> , 2013 , 53, 782-786	0-1	1
8	Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infection. <i>International Journal of Clinical Oncology</i> , 2012 , 17, 462-9	4-2	6
7	Two Lung Cancer Patients with HIV Infection Who Underwent Adjuvant Chemotherapy Followed by Surgery. <i>Japanese Journal of Lung Cancer</i> , 2012 , 52, 284-289	0-1	1
6	Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity. <i>Lung Cancer</i> , 2011 , 74, 492-6	5-9	31
5	S-1 is an active anticancer agent for advanced thymic carcinoma. <i>Lung Cancer</i> , 2010 , 70, 357-63	5-9	27
4	Long-term survival following metachronous intratumoral hemorrhage in an HIV-infected patient with lung cancer. <i>International Journal of Clinical Oncology</i> , 2010 , 15, 515-8	4-2	1
3	Acute adverse effects of radiation therapy on HIV-positive patients in Japan: study of 31 cases at Tokyo Metropolitan Komagome Hospital. <i>Journal of Radiation Research</i> , 2010 , 51, 749-53	2-4	5
2	Choroidal metastasis in a patient with small cell lung cancer discovered during treatment with chemotherapy. <i>International Journal of Clinical Oncology</i> , 2009 , 14, 541-4	4-2	8
1	A case of polymyositis in a chronic hepatitis C patient treated with peg-interferon-alpha 2b and ribavirin therapy. <i>Clinical Journal of Gastroenterology</i> , 2009 , 2, 346-350	1-1	2